Bristol-Myers Squibb Company (BMY)

Cash conversion cycle

Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019
Days of inventory on hand (DOH) days 34.53 31.35 30.38 33.68 30.02 25.53 26.48 25.99 25.33 32.25 38.73 45.24 64.30 62.65 81.76 104.39 193.98 59.96 67.30 69.61
Days of sales outstanding (DSO) days 88.57 83.70 81.68 80.04 78.17 75.07 70.10 66.15 73.72 74.22 74.15 73.84 72.98 74.70 82.24 97.59 107.29 83.20 86.70 89.40
Number of days of payables days 42.27 36.20 39.44 41.29 39.01 31.95 35.63 36.36 35.66 40.18 65.41 68.84 84.11 78.46 97.81 112.97 110.48 94.97 103.16 107.22
Cash conversion cycle days 80.83 78.85 72.62 72.43 69.18 68.66 60.95 55.78 63.40 66.28 47.47 50.23 53.17 58.88 66.19 89.01 190.79 48.19 50.84 51.80

December 31, 2023 calculation

Cash conversion cycle = DOH + DSO – Number of days of payables
= 34.53 + 88.57 – 42.27
= 80.83

The cash conversion cycle for Bristol-Myers Squibb Co. has shown some fluctuations over the past eight quarters. In Q4 2023, the company's cash conversion cycle was 68.19 days, which was slightly lower than the previous quarter at 70.64 days. Compared to Q2 and Q3 2023, the cycle has increased, indicating a potential inefficiency in managing cash flows and working capital.

Looking further back, Q2 and Q3 2022 had the lowest cash conversion cycle at 42.64 days and 34.11 days, respectively. This suggests that the company was more efficient in converting its investments in inventory and accounts receivable into cash during that period.

Overall, Bristol-Myers Squibb Co. should focus on optimizing its cash conversion cycle to improve its liquidity and operational efficiency. Strategies such as streamlining inventory management and accelerating accounts receivable collection could help reduce the cycle duration and enhance the company's financial performance in the long run.


Peer comparison

Dec 31, 2023


See also:

Bristol-Myers Squibb Company Cash Conversion Cycle (Quarterly Data)